Estimates of the duration of the early and late stage of gambiense sleeping sickness
Open Access
- 8 February 2008
- journal article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 8 (1) , 16
Abstract
The durations of untreated stage 1 (early stage, haemo-lymphatic) and stage 2 (late stage, meningo-encephalitic) human African trypanosomiasis (sleeping sickness) due to Trypanosoma brucei gambiense are poorly quantified, but key to predicting the impact of screening on transmission. Here, we outline a method to estimate these parameters.Keywords
This publication has 23 references indexed in Scilit:
- Aparasitemic serological suspects in Trypanosoma brucei gambiense human African trypanosomiasis: A potential human reservoir of parasites?Acta Tropica, 2006
- Diagnostic and neuropathogenesis issues in human African trypanosomiasisInternational Journal for Parasitology, 2006
- Eflornithine Is Safer than Melarsoprol for the Treatment of Second-Stage Trypanosoma brucei gambiense Human African TrypanosomiasisClinical Infectious Diseases, 2005
- Quantifying the level of under‐detection of Trypanosoma brucei rhodesiense sleeping sickness casesTropical Medicine & International Health, 2005
- Options for Field Diagnosis of Human African TrypanosomiasisClinical Microbiology Reviews, 2005
- The epidemiology and control of human African trypanosomiasis2001
- Follow‐up of Card Agglutination Trypanosomiasis Test (CATT) positive but apparently aparasitaemic individuals in Côte d'Ivoire: evidence for a complex and heterogeneous populationTropical Medicine & International Health, 2000
- Control strategies for sleeping sickness in Central Africa: a model‐based approachTropical Medicine & International Health, 1996
- Persistence of antibodies to Trypanosoma brucei gambiense after treatment of human trypanosomiasis in UgandaThe Lancet, 1992
- A general model for the African trypanosomiasesParasitology, 1988